icon3

Circulating Tumor Cells Market By Technology Type (CTC Enrichment, CTC Analysis, Others) By Application (Tumorigenesis Research, Cancer Stem Cell Research Others) Regional Analysis & Forecast– 2026

  • OI-64
  • |
  • Published date: Jan, 2019
  • |
  • Oncology/Hematology
  • |
  • Pages

Introduction:



  • Circulating Tumor Cells (CTCs) are cancer cells that detach from a primary tumor and travel through the bloodstream or lymphatic system to other parts of the body. Circulating tumor cell detection test possesses the ability to detect, quantify, and analyze tumor cells in the blood of cancer patients. Circulating tumor cells tests are applicable in the characterization of tumor cells through biochemical marker analysis. CTC isolation, detection, and molecular characterization systems find investigational application in prostate, breast, colon, head, neck, skin, lung, and pancreatic cancer.


Market overview:



  • The global circulating tumor cells (CTC) market size was estimated at XX billion in 2018 and is expected to grow at a double-digit growth rate during the forecast period and registering a CAGR of ….% from 2018 to 2026. Increasing demand for preventive medicine, thus influencing the demand for CTC tests is a key factor that is expected to boost the market growth. According to NIH, National Cancer Institute, cancer is one of the major reasons for death globally, In 2012, there were around 8.2 million cancer-related death and 14.1 million new cases of cancer globally and by 2030 the number of new cases of cancer is expected to reach more than 23 million new cancer cases are identified annually in that top 5 cancers account for 50% of patients, 8.2 million cancer deaths annually and 10 million patients annually have Stage IV metastatic disease.


Segmentation:



  • The global circulating tumor cells market has segmented based on technology CTC Enrichment, CTC Analysis, and CTC Detection which further segmented into in-vivo positive selection, ex-vivo positive selection, microchips, negative selection, and single spiral micro channel. the CTC detection segment is further divided into immunocytochemical technologies, molecular (RNA) based technologies, xenotransplantation models, EPISOT functional in-vitro cell culture and functional in-vitro cell invasion assay. On the basis of application, CTCs market is bifurcated into EMT biomarkers development, tumorigenesis research, cancer stem cell research, and others.


Technology:

Based on technology, the market is categorized into ex-vivo positive selection technology, in-vivo positive selection, negative selection, microchips & single spiral micro channel. CTC enrichment methods have occupied a market revenue share of over 45.0% of the total market it is anticipated that it shall witness lucrative growth over the forecast period and these techniques for CTC detection include enrichment using magnetic beads, centrifugal force, filtration, and other physical properties such as size, density, deformity, and electric charges


Geography: Americas, APAC, EMEA


North America is estimated to witness a high growth rate in this market due to the well-established healthcare infrastructure with high addition of advanced diagnostic technologies and rising


According to publications, Asia Pacific is estimated to witness significant growth over the next decade with a CAGR of around 13.4%, Growth is mainly led by the technologically advanced countries like China & Japan, which are effectively pushing for better techniques to detect and monitor cancer


According to the National Center for Biotechnology Information (NCBI) stated that the projected cases of prostate cancer all over India for the year 2015 were 28,079. Furthermore, the Leukemia & Lymphoma Society estimated that around, 60,300 people are expected to be diagnosed with leukemia in 2018. The significant growth in the population of cancer patients is fueling for the growth of the circulating tumor cells market. 


Key Developments:



  • Biocept Inc received a patent for its Target Selector assays for molecular analysis to improve the patient diagnosis with cancer in China.

  • Natera, a company involved in non-invasive genetic testing and the analysis of circulating cell-free DNA, to present successful results of Signatera, to monitor colorectal cancer and identify disease recurrence.



 

 

 

Report Description: The report covers in-depth analysis of Circulating Tumor Cell (CTC) tests currently in development. The report assesses the pipeline Circulating Tumor Cell (CTC) test by stage of development (early development, pre-clinical, Clinical and In Approval), by application (Breast, Lung, Liver, Colorectal, Prostate, and others). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement patent, and regulatory designations.


The report includes in-depth company profiles of key players in the Circulating Tumor Cell (CTC) test market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments.


The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.


Scope:



  • Provides a comprehensive understanding of Circulating Tumor Cell (CTC)

  • Includes all-inclusive pipeline product coverage with segregation by various stages of the pipeline from Early development to In Approval.

  • Provides a comparative analysis of key marketed products and pipeline tests

  • Provides key information on players involved in Circulating Tumor Cell (CTC) tests

  • Provides in-depth coverage of key news related to Circulating Tumor Cell (CTC) tests, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates.



 

 

 

Our research works on a holistic 360° approach to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involve the following steps:




  • Data Collation (Primary & Secondary)




  • In-house Estimation (Based on proprietary databases and Models)




  • Market Triangulation




  • Forecasting




  • Market-related information is assembled from both primary and secondary sources. 






  • Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services. 






  • Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others. 






  • Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained. 




 


REPORT YOU MIGHT BE INTERESTED

Choose Licence Type

$3,850.00
$4,950.00


(For Corporate Licence Only) Complementary
Credit card Logo
Inquiry Before Buying

Related Reports


Contact Us

Email Us at: sales@optimainsights.org | Reach Us at: +91 966 6620 365 | +1 424 2554 365 (US)